pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Apr 27·1 min read
save

Revolution Medicines threatens to sue Erasca over patent, efficacy claims

Earlier this month, a new cancer drug captivated patients and investors. Now the lawyers get their turn. On Monday, Erasca said it had received a legal threat from Revolution Medicines' lawyers over its cancer drug ...

Apr 27, 2026·read at Endpoints ↗

April 27, 2026 02:17 PM EDT R&DChinaLaw Rev­o­lu­tion Med­i­cines threat­ens to sue Eras­ca in show­down over close­ly watched RAS drugs Max Bayer Senior Reporter Ear­li­er this month, a new can­cer drug cap­ti­vat­ed pa­tients and in­vestors. Now the lawyers get their turn. On Mon­day, the biotech Eras­ca said it had … Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
84 words · retrieved Apr 27
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Erasca, Inc.2
topics
Oncology2KRAS

related stories

  • Jul 14Erasca's $550M offering; Summit sells an antibioticEndpoints
  • Apr 28FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ resultsBioPharma Dive
  • Apr 27STAT+: Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapySTAT
  • Apr 27Erasca reports RAS cancer drug data after legal threat from RevolutionEndpoints
  • May 6Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myelomaonclive